Key facts
- Verinomics’s last known valuation is $37.0M (May 2025).
- It has raised $12.0M across 1 recorded rounds; the latest was Seed Round ($2.0M) in Dec 2018.
- Notable investors include US National Science Foundation, U.S. Department of Energy, University of California, United States Department of Agriculture, Fulcrum Global Capital — 9 tracked in total.
- Verinomics has filed 1 Form D with the SEC, most recently Jan 2019 ($2.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Verinomics
Funding rounds
1 roundsAbout Verinomics
Operator of genomic and computational technology development firm intended to identify trait genes and develop comprehensive workflows specific to client's crop. The company's solutions use genomics, data analytics and gene editing to offer complete integration of trait gene identification, breeding analytics, marker deployment and custom gene editing, enabling clients to accelerate product development and trait discovery.
- Sector
- Materials and Resources
- HQ
- New Haven, CT, United States
- Founded
- 2016
- Employees
- 18
- Website
- verinomics.com/
- Ownership
- Privately Held (backing)
Verinomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verinomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verinomics in its N-PORT filings yet. We sweep new filings monthly.